Sponsor:	IO Biotech ApS
Protocol Number:	IO102-012
EudraCT Number:	2018-000139-28
Date of Clinical Study Report:	19 May 2023

The following table and figures have been extracted from the final IO102-012 Clinical Study Report (dated 19 May 2023) and present a summary of the results of progression free survival (PFS).

<u>Secondary Endpoint: Progression Free Survival – Both Phases</u>

Number of Patients (ITT Population)	Cohort A		Cohort B	
	Exp A1[1] N=38	Control A2[2] N=16	Exp B1[3] N=39	Control B2[4] N=17
No. of PFS events	31 (81.6%)	11 (68.8%)	36 (92.3%)	15 (88.2%)
Median months to event And 95% CI	6.5 [4.0 ; 14.7]	6.3 [3.9 ; 32]	9.0 [6.0 ; 11.0]	10.1 [6.4 ; 15]
Kaplan Meier estimates				
At month 6	55.3%	56.3%	66.7%	81.3%
At month 9	42.1%	49.2%	51.3%	56.3%
At month 12	39.5%	35.2%	33.3%	37.5%
By PD-L1 expression:				
TPS <1%	-	-	N=20	N=6
No. of PFS events	-	-	20 (100%)	6 (100%)
Median months to event And 95% CI	- -	- -	7.1 [4.1 ; 10.9]	12.6 [5.9 ; -]
Kaplan Meier estimates				
At month 6	-	-	60.0%	83.3%
At month 9	-	-	35.0%	66.7%
At month 12	-	-	25.0%	50.0%
TPS 1-49%	-	-	N=19	N=11
No. of PFS events	-	-	16 (84.2%)	9 (81.8%)
Median months to event And 95% CI	- -	- -	10.6 [6.0 ; 17.1]	9.2 [2.0 ; 12.2]

Number of Patients (ITT Population)	Cohort A		Cohort B	
	Exp A1[1] N=38	Control A2[2] N=16	Exp B1[3] N=39	Control B2[4] N=17
Kaplan Meier estimates				
At month 6	-	-	73.7%	80.0%
At month 9	-	-	68.4%	50.0%
At month 12	-	-	42.1%	30.0%

For median months to event, missing numbers mean that these numbers could not be calculated.

[1] Exp A1 = Arm A (Phase I) + Arm A1 (Phase II)

[2] Control A2 = Arm A2 (Phase II)

[3] Exp B1 = Arm B (Phase I) + Arm B1 (Phase II)

[4] Control B2 = Arm B2 (Phase II)

Secondary Endpoint: Progression Free Survival – Kaplan Meier Plot – Both Phases – Cohort A

	Patients	Events
IO102	38	31
Pembro	16	11

Number at risk

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36
IO102	38	29	25	21	17	16	15	15	13	12	10	10	10	10	8	6	4	4	1
Pembrolizumab	16	15	12	9	7	7	5	5	5	5	5	5	5	4	4	3	1	0	

Secondary Endpoint: Progression Free Survival – Kaplan Meier Plot – Both Phases – Cohort B